Impact of the Quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program

Pediatric Infectious Disease Journal

Volumn 25, Issue 4, 2006, Pages 372-374

  Gîlca, Vladimir ^a,c   Duval, Bernard ^a,b   Boulianne, Nicole ^a,b   Dion, Réjean ^a   De Serres, Gaston ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b University Laval   (Canada)

^c NONE   (Canada)

Author keywords

Case preventability; Hepatitis B; Immunization program impact; Risk factors; Vaccine failures

Indexed keywords

HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANADA; CHILD; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS B; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL HEALTH SERVICE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; MALE; PROGRAM EVALUATION; QUEBEC; TREATMENT OUTCOME;

EID: 33645551165     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000207468.04665.ad     Document Type: Article

References (11)

1. National Advisory Committee on Immunization. Lignes directrices révisées relatives aux vaccins de rappel contre l'hépatite B. Union Med Canada. 1993;47.
2. Organisation Mondiale de la Santé. Déclaration sur le vaccin contre l'hépatite B. Relevé Épidemiol Hebdomadaire. 1993;19:104-115.
3. Centers for Disease Control and Prevention. Hepatitis B vaccination of adolescents: California, Louisiana, and Oregon, 1992-1994. JAMA. 1994;12:272(14):1096-1097.
4. National Advisory Committee on Immunization. Canadian Immunization Guide. 6th ed. Ottawa, Canada: Public Health Agency of Canada; 2002.
5. Manitoba Schools Science Symposium. Surveillance des MADO au Québec Définition Nosologique. 2004.
6. Duval B, Boulianne N, De Serres G, et al. Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children. Vaccine. 2000;18:1467-1472.
7. Incidence of acute hepatitis B: United States, 1990-2002. MMWR. 2004;52(51-52):1252-1254.
8. Patrick DM, Bigham M, Ng H, White R, Tweed A, Skowronski DM. Elimination of acute hepatitis B among adolescents after one decade of an immunization program targeting grade 6 students. Pediatr Infect Dis J. 2003;22:874-877.
9. Salleras L, Dominguez A, Bruguera M, et al. Dramatic decline in acute hepatitis B infection and disease incidence rates among adolescents and yoimg people after 12 years of a mass hepatitis B vaccination programme of pre-adolescents in the schools of Catalonia (Spain). Vaccine. 2005;23(17-18):2181-2184.
10. Shepard CW, Finelli L, Fiore AE, Bell BP. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr Infect Dis J. 2005;24:755-760.
11. Giacchino R, Zancan L, Vajro P, et al. Hepatitis B virus infection in native versus immigrant or adopted children in Italy following the compulsory vaccination. Infection. 2001;29: 188-191.